Polygenic risk scores in healthcare contexts: what's the scope? An interview study of European healthcare providers and researchers' perspectives on ethical challenges.

IF 3.4 2区 生物学 Q2 GENETICS & HEREDITY
Human Genetics Pub Date : 2025-12-01 Epub Date: 2025-10-27 DOI:10.1007/s00439-025-02792-4
Lara Andreoli, Hilde Peeters, Kristel Van Steen, Kris Dierickx
{"title":"Polygenic risk scores in healthcare contexts: what's the scope? An interview study of European healthcare providers and researchers' perspectives on ethical challenges.","authors":"Lara Andreoli, Hilde Peeters, Kristel Van Steen, Kris Dierickx","doi":"10.1007/s00439-025-02792-4","DOIUrl":null,"url":null,"abstract":"<p><p>In the last decade, substantial research efforts have started worldwide to foster the clinical translation of Polygenic Risk Scores (PRS). Understanding the views of key relevant groups becomes timely to critically inform the socio-ethical debate, impact future health policy, and support the development of guidelines for best practices in healthcare contexts. We performed 26 in-depth semi-structured interviews to investigate the perspectives of European researchers and healthcare providers from different specialties (clinical genetics, oncology, cardiology, psychiatry) on the ethical and social implications of PRS uses in healthcare contexts. Findings were conceptualized in four main themes: 1) appropriate clinical use, highlights that PRS should be considered complementary tools aimed at informing a clinical intervention, with notions of appropriateness differing according to clinical goals and condition-type; 2) clinical utility: what's the evidence? captures participants' orientations towards the capability of PRS to improve health outcomes compared to standard care, as well as the barriers, limitations, or emerging areas of utility; 3) balancing risk and responsibility: navigating ethical questions in patient care, addresses classical issues in clinical genetics, including communication and counselling, potential patient harms, relevance of PRS information to family members, and the use of PRS in pediatric settings; 4) searching for standards: clinical guidelines, gathers perspectives on the potential format and content of future clinical guidelines, relevant parties, and contexts of applicability. In conclusion, the present study outlines a framework to define the range of responsible uses in healthcare contexts; however, societal and public health considerations, including priority-setting in national healthcare systems, need to follow for a comprehensive, and contextual, evaluation of PRS.</p>","PeriodicalId":13175,"journal":{"name":"Human Genetics","volume":" ","pages":"1229-1244"},"PeriodicalIF":3.4000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Genetics","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1007/s00439-025-02792-4","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

Abstract

In the last decade, substantial research efforts have started worldwide to foster the clinical translation of Polygenic Risk Scores (PRS). Understanding the views of key relevant groups becomes timely to critically inform the socio-ethical debate, impact future health policy, and support the development of guidelines for best practices in healthcare contexts. We performed 26 in-depth semi-structured interviews to investigate the perspectives of European researchers and healthcare providers from different specialties (clinical genetics, oncology, cardiology, psychiatry) on the ethical and social implications of PRS uses in healthcare contexts. Findings were conceptualized in four main themes: 1) appropriate clinical use, highlights that PRS should be considered complementary tools aimed at informing a clinical intervention, with notions of appropriateness differing according to clinical goals and condition-type; 2) clinical utility: what's the evidence? captures participants' orientations towards the capability of PRS to improve health outcomes compared to standard care, as well as the barriers, limitations, or emerging areas of utility; 3) balancing risk and responsibility: navigating ethical questions in patient care, addresses classical issues in clinical genetics, including communication and counselling, potential patient harms, relevance of PRS information to family members, and the use of PRS in pediatric settings; 4) searching for standards: clinical guidelines, gathers perspectives on the potential format and content of future clinical guidelines, relevant parties, and contexts of applicability. In conclusion, the present study outlines a framework to define the range of responsible uses in healthcare contexts; however, societal and public health considerations, including priority-setting in national healthcare systems, need to follow for a comprehensive, and contextual, evaluation of PRS.

医疗环境中的多基因风险评分:范围是什么?欧洲医疗保健提供者和研究人员对伦理挑战的看法的访谈研究。
在过去的十年中,世界范围内已经开始了大量的研究工作,以促进多基因风险评分(PRS)的临床翻译。了解关键相关群体的观点是及时的,可以为社会伦理辩论提供重要信息,影响未来的卫生政策,并支持制定医疗保健环境中最佳做法的指导方针。我们进行了26次深入的半结构化访谈,以调查来自不同专业(临床遗传学、肿瘤学、心脏病学、精神病学)的欧洲研究人员和医疗保健提供者对PRS在医疗保健环境中使用的伦理和社会影响的观点。研究结果被概念化为四个主题:1)适当的临床使用,强调PRS应被视为旨在告知临床干预的补充工具,根据临床目标和病情类型,适当性的概念不同;2)临床应用:有什么证据?反映了参与者对与标准护理相比,PRS改善健康结果的能力的倾向,以及障碍、限制或新出现的实用领域;3)平衡风险和责任:引导患者护理中的伦理问题,解决临床遗传学中的经典问题,包括沟通和咨询,潜在的患者危害,PRS信息与家庭成员的相关性,以及PRS在儿科环境中的使用;4)标准搜索:临床指南,收集对未来临床指南的潜在格式和内容、相关方和适用性背景的观点。总之,本研究概述了一个框架,以确定卫生保健环境中负责任的使用范围;然而,社会和公共卫生方面的考虑,包括在国家卫生保健系统中确定优先事项,需要遵循对减贫战略进行全面和背景性评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Human Genetics
Human Genetics 生物-遗传学
CiteScore
10.80
自引率
3.80%
发文量
94
审稿时长
1 months
期刊介绍: Human Genetics is a monthly journal publishing original and timely articles on all aspects of human genetics. The Journal particularly welcomes articles in the areas of Behavioral genetics, Bioinformatics, Cancer genetics and genomics, Cytogenetics, Developmental genetics, Disease association studies, Dysmorphology, ELSI (ethical, legal and social issues), Evolutionary genetics, Gene expression, Gene structure and organization, Genetics of complex diseases and epistatic interactions, Genetic epidemiology, Genome biology, Genome structure and organization, Genotype-phenotype relationships, Human Genomics, Immunogenetics and genomics, Linkage analysis and genetic mapping, Methods in Statistical Genetics, Molecular diagnostics, Mutation detection and analysis, Neurogenetics, Physical mapping and Population Genetics. Articles reporting animal models relevant to human biology or disease are also welcome. Preference will be given to those articles which address clinically relevant questions or which provide new insights into human biology. Unless reporting entirely novel and unusual aspects of a topic, clinical case reports, cytogenetic case reports, papers on descriptive population genetics, articles dealing with the frequency of polymorphisms or additional mutations within genes in which numerous lesions have already been described, and papers that report meta-analyses of previously published datasets will normally not be accepted. The Journal typically will not consider for publication manuscripts that report merely the isolation, map position, structure, and tissue expression profile of a gene of unknown function unless the gene is of particular interest or is a candidate gene involved in a human trait or disorder.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书